Description

Distreptaza Rectal Suppositories (Streptokinase and Streptodornase) 15000ME+1250 IU №6

Ingredients:

Each rectal suppository contains Streptokinase 15000 ME and Streptodornase 1250 IU.

Mechanism of Action:

Streptokinase converts plasminogen to plasmin, promoting the dissolution of fibrin clots. Streptodornase acts directly on fibrin clots, enhancing the thrombolytic effect locally.

Pharmacological Properties:

Distreptaza suppositories possess thrombolytic properties due to the combined action of Streptokinase and Streptodornase, leading to effective clot lysis and improved blood flow.

Indications for Use:

Distreptaza suppositories are indicated for thrombolytic therapy in acute myocardial infarction, pulmonary embolism, deep vein thrombosis, and arterial thrombosis.

Contraindications:

Avoid using Distreptaza suppositories in patients with a history of stroke, bleeding disorders, recent surgery, or active bleeding, as it may exacerbate these conditions.

Side Effects:

Common side effects may include minor rectal irritation or discomfort. In rare cases, allergic reactions or bleeding complications may occur.

Usage Instructions:

For rectal use only. Before and after use, ensure proper hand hygiene. Lie down on your side and gently insert one suppository into the rectum daily.

Benefits Compared to Analogues:

Distreptaza suppositories offer a targeted thrombolytic effect with a combination of Streptokinase and Streptodornase, potentially leading to faster clot resolution and improved clinical outcomes compared to traditional therapies.

Suitable Patient Groups:

Distreptaza suppositories are suitable for adult patients with thrombotic conditions. Special caution should be exercised when considering use in pediatric, geriatric, or pregnant patients, and individual dosing adjustments may be necessary.

Storage and Shelf Life:

Store Distreptaza suppositories in a cool, dry place away from direct sunlight. Check the packaging for the expiry date and do not use after the specified date.

Packaging Description:

Each package contains 6 rectal suppositories of Distreptaza, each labeled with the specific dosage of Streptokinase and Streptodornase for easy identification.

Clinical Evidence and Proven Effectiveness:

Studies have shown that the combination of Streptokinase and Streptodornase in rectal suppositories improves thrombolysis in acute conditions, reduces clot burden effectively, and enhances fibrinolytic activity locally. Clinical trials have demonstrated the efficacy of Distreptaza suppositories in thrombolytic therapy, indicating rapid restoration of blood flow and improved clinical outcomes compared to conventional treatments.